David Shaw’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

David Shaw’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-44,442	Closed	-$1.82M	–	5026
2024 Q2	$1.82M	Sell	44,442 -377,573	-89%	-$15.7M	﹤0.01%	2730
2024 Q1	$17.8M	Buy	+422,015	New	+$17.7M	0.02%	983
2022 Q1	–	Sell	-8,700	Closed	-$282K	–	6055
2021 Q4	$282K	Sell	8,700 -14,881	-63%	-$525K	﹤0.01%	4709
2021 Q3	$696K	Buy	+23,581	New	+$662K	﹤0.01%	3870

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

David Shaw's CERE Position: Q3 2024 in Review

David Shaw sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 44,442 shares — an estimated $1.82M sold.

David Shaw first reported a position in CERE in Q3 2021 and held it in 4 quarters. The position peaked at $17.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

David Shaw reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
David Shaw sold 44,442 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.82M.
David Shaw first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
David Shaw's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $17.8M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.